Parmax Pharma Ltd — Updates, 30-05-2025: Company Update

Parmax Pharma has announced a board meeting on to consider the financial results for the quarter and half-year. The company reported revenue from operations of Rs 4.83 Cr for the quarter and Rs 28.20 Cr for the year, with a net loss of Rs 1.49 Cr and Rs 2.09 Cr respectively. The losses reflect the impact of a fire incident at the manufacturing facility causing asset damage valued at Rs 3.69 Cr. Insurance claims are in process but yet to be finalized. The company’s total equity remains negative at Rs 1.99 Cr, and borrowings stand at Rs 77.04 Cr. Cash flow from operations is negative, reflecting ongoing financial stress. An investment of Rs 40 lakh in a mutual fund was noted, which does not comply with certain regulatory provisions. The statutory auditor has issued an unqualified report but highlighted this fire-related asset loss and the investment irregularity.